Opendata, web and dolomites

JEM Phase 1

JEM: The world safest subcutaneous, enclosed, biocompatible implantable device, attached directly to a AV fistula or graft or vein, for chronic disease patients in need of repetitive vascular access

Total Cost €


EC-Contrib. €






 JEM Phase 1 project word cloud

Explore the words cloud of the JEM Phase 1 project. It provides you a very rough idea of what is the project "JEM Phase 1" about.

offers    back    chemotherapy    position    enclosed    made    easier    vascular    8k    requiring    dialysis    player    eliminates    victims    causing    transfusions    estimate    patients    safer    longevity    techniques    fistula    digestive    specially    hematomas    save    blood    patented    attached    device    medications    undergo    gold    gauge    company    wall    medical    blunt    market    perforation    repetitive    spot    clinicians    lowering    potentially    flow    markets    solutions    period    burn    conservative    jem    provides    healthcare    repair    patient    accurate    thereby    prevents    improves    sold    larger    pediatric    home    standard    needle    hemolysis    seek    puncturing    usually    morbidity    technique    buttonhole    disorders    continually    risk    receiving    hemodialysis    lifespan    pain    first    mortality    clinical    multiplied    oncology    implantable       reduces    times    graft    life    200m    designed    savings    replacement    universal    vein    reducing    regular    trained    operations    subcutaneous    advantages   

Project "JEM Phase 1" data sheet

The following table provides information about the project.


Organization address
address: 11 HAGRA STREET
postcode: 4252008
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-06-01   to  2016-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ACCESS FOR LIFE IL (NETANYA) coordinator 50˙000.00


 Project objective

'JThe JEM project aims to bring to the healthcare and medical device markets the first subcutaneous enclosed implantable device attached directly to a vein, fistula or graft. The JEM is based on a patented design that greatly improves repetitive vascular access techniques and provides safer, more accurate and effective results. The JEM provides the following advantages: • It is based on the European Gold Standard 'buttonhole technique' for vascular access. • It greatly reduces costs by reducing the need for fistula repair & replacement. • It enables repetitive puncturing at the same spot by less-trained clinicians. • Its 6-year lifespan, 3 times the average fistula lifespan, reduces mortality & morbidity. • Its specially designed needle prevents back wall perforation and hematomas. • It will allow for a larger gauge needle thereby potentially increasing blood flow and lowering the risk of hemolysis. • It can be made to use a unique blunt needle that is sold by Access for Life, causing less pain to the patients ensuring easier and safer home hemodialysis. JEM devices from Access for Life are designed for all patients in need of repetitive vascular access: hemodialysis patients, oncology patients receiving chemotherapy, patients with blood disorders, patients requiring regular medications or blood transfusions, burn victims, pediatric patients and patients with digestive disorders. Due to its longevity, JEM eliminates three of the four operations dialysis patients usually undergo in a 6-year period. This will save healthcare systems about 5,8K € per dialysis patient. Multiplied by the growing number of patients, a conservative estimate of potential savings is over 200M € a year. Through the JEM project, we seek to position our company as the leading player in medical devices for repetitive vascular access, a market that is continually growing. Access for Life offers universal solutions for a wide range of clinical applications that require vascular access.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "JEM PHASE 1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "JEM PHASE 1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

SEQURE (2018)

Targeted complete next-generation sequencing for companion diagnostics and personalized treatment of cancer

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More